MONOCLONAL ANTIBODIES DIRECTED AGAINST HUMAN C5 AND C8 BLOCK COMPLEMENT‐MEDIATED DAMAGE OF XENOGENEIC CELLS AND ORGANS

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Transplantation

• Publication date

  1995-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00007890-199512000-00017PMID 8525523
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Complement in human diseases: looking towards the 21st century.

  1995cited by this paper
• Removal Of Baboon And Human Antiporcine Igg And Igm Natural Antibodies By Immunoadsorption: Results of In Vitro And In Vivo Studies

  1995cited by this paper
• Protection of porcine aortic endothelial cells from complement-mediated cell lysis and activation by recombinant human CD59.

  1994cited by this paper
• The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts.

  1994cited by this paper
• Evidence that intravenously administered alpha-galactosyl carbohydrates reduce baboon serum cytotoxicity to pig kidney cells (PK15) and transplanted pig hearts.

  1994cited by this paper
• REMOVAL OF NATURAL HUMAN XENOANTIBODIES TO PIG VASCULAR ENDOTHELIUM BY PERFUSION OF BLOOD THROUGH PIG KIDNEYS AND LIVERS

  1993cited by this paper
• Prolongation of cardiac xenograft survival by depletion of complement.

  1993cited by this paper
• Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts.

  1993cited by this paper
• Overview of in vivo xenotransplantation studies: prospects for the future.

  1992cited by this paper
• Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients.

  1992cited by this paper
• Effects of complement activation in the isolated heart. Role of the terminal complement components.

  1992cited by this paper
• Biologic activity of synthetic analogues of C5a anaphylatoxin.

  1992cited by this paper
• Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.

  1991cited by this paper
• The role of C5a and antibody in the release of heparan sulfate from endothelial cells

  1991cited by this paper
• Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies.

  1991cited by this paper
• Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection.

  1991cited by this paper
• Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59.

  1990cited by this paper
• The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.

  1990cited by this paper
• Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex.

  1990cited by this paper
• Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection

  1990cited by this paper
• Homologous species restriction of the complement-mediated killing of nucleated cells.

  1990cited by this paper
• Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface.

  1989cited by this paper
• Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects.

  1989cited by this paper
• Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

  1989cited by this paper
• Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response.

  1988cited by this paper
• Complement C5b-9-stimulated platelet secretion is associated with a Ca2+-initiated activation of cellular protein kinases.

  1987cited by this paper
• Effect of complement proteins C5b-9 on blood platelets. Evidence for reversible depolarization of membrane potential.

  1985cited by this paper
• Purification from guinea pig erythrocyte stroma of a decay-accelerating factor for the classical c3 convertase, C4b,2a.

  1981cited by this paper
• Mechanism of cytolysis by complement.

  1972cited by this paper

• Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species

  2020cites this paper
• Development of flow cytometric opsonophagocytosis and antibody-mediated complement deposition assays for non-typeable Haemophilus influenzae

  2018cites this paper
• Microbial Neuraminidase Induces a Moderate and Transient Myelin Vacuolation Independent of Complement System Activation

  2017cites this paper
• Complement system activation contributes to the ependymal damage induced by microbial neuraminidase

  2016cites this paper
• A novel recombinant fibrinogenase of Agkistrodon acutus venom protects against hyperacute rejection via degradation of complements.

  2013cites this paper
• Galectin-3-Mediated Xenoactivation of Human Monocytes

  2009cites this paper
• Development of cancer immunotherapeutics targeting complement regulatory protein CD55.

  2007cites this paper
• Strategies of therapeutic complement inhibition.

  2006cites this paper
• Ultrastructure as a Diagnostic Adjunct in the Evaluation of Lung Allograft Biopsies

  2005cites this paper
• Complement System in Allorecognition and Rejection of Organ Transplants

  2004cites this paper
• Therapeutic Manipulation of the Complement System

  2004cites this paper
• The past, present, and future of xenotransplantation.

  2004cites this paper
• Perspectives on complement in xenotransplantation.

  2003cites this paper
• Association of Humoral Immunity and Bronchiolitis Obliterans Syndrome

  2003cites this paper
• The Complement Barrier to Xenotransplantation

  2002cites this paper
• Antibody-mediated activation of the classical complement pathway in xenograft rejection.

  2002cites this paper
• Humorally mediated posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a hypothesis

  2002cites this paper
• Therapeutic Strategies for Xenotransplantation

  2001cites this paper
• The Complement System as a Hurdle to Xenotransplantation

  2001cites this paper
• Human serum-induced expression of E-selectin on porcine aortic endothelial cells in vitro is totally complement mediated.

  2001cites this paper
• Manipulation of the Humoral Immune System and the Host Immune Response to Infection

  2001cites this paper
• Complement Regulation and the Host Response to Infection

  2001cites this paper
• Targeting complement in therapy

  2001cites this paper
• Inhibition of Complement in the Membrane Attack Pathway

  2000cites this paper
• Long-term survival of nonhuman primates receiving life-supporting transgenic porcine kidney xenografts.

  2000cites this paper
• Regulators of the anaphylatoxin C5a

  2000cites this paper
• Graft-specific inhibition of complement activation after xenotransplantation; genetically modified pig organs versus systemic anticomplement strategies.

  2000cites this paper
• Xenotransplantation: how to overcome the complement obstacle?

  1999cites this paper
• Inhibition of Complement as a Therapeutic Approach in Inflammatory Central Nervous System (CNS) Disease

  1999cites this paper
• Regulation of the complement membrane attack pathway.

  1999cites this paper
• Molecular and Cellular Basis of Inflammation

  1999cites this paper
• Role of Complement in Endothelial Cell Activation

  1999cites this paper
• Complement inhibition with an anti-C5 monoclonal antibody prevents hyperacute rejection in a xenograft heart transplantation model.

  1999cites this paper
• Hyperacute rejection models: ex vivo xenoperfusion systems.

  1999cites this paper
• Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation.

  1999cites this paper
• Selection of phage-displayed anti-guinea pig C5 or C5a antibodies and their application in xenotransplantation.

  1999cites this paper
• Endothelial cell activation

  1998cites this paper
• Therapeutic inhibition of the complement system.

  1998cites this paper
• Monitoring of microhemodynamic changes during ex vivo xenogeneic liver perfusion using intravital microscopy

  1998cites this paper
• Therapeutic uses of recombinant complement receptors.

  1998cites this paper
• Endothelial cell activation.

  1998cites this paper
• Potential of Anticomplement Therapy in Clinical Transplantation

  1998cites this paper
• Development of Clinically Useful Agents to Control Complement-Mediated Tissue Damage

  1998cites this paper
• Effect of Transgenic Expression of Human Decay—Accelerating Factor on the Inhibition of Hyperacute Rejection of Pig Organs

  1997cites this paper
• Strategies for preventing porcine xenograft rejection: recent progress and future developments

  1997cites this paper
• Overcoming rejection in pig-to-primate cardiac xenotransplantation.

  1997cites this paper
• Controlling the complement system in inflammation.

  1997cites this paper
• Role of Complement in Xenograft Rejection

  1997cites this paper
• Molecular targets for genetic engineering in pig-to-human vascularized xenotransplantation

  1997cites this paper
• Characterization of pigs transgenic for human decay-accelerating factor.

  1997cites this paper
• The prospects for xenotransplantation of the kidney

  1997cites this paper
• [Xenotransplantation in man. 2: Control of rejection and application to xenotransplantation of the swine liver in man].

  1996cites this paper
• In vitro accommodation of immortalized porcine endothelial cells: resistance to complement mediated lysis and down-regulation of VCAM expression induced by low concentrations of polyclonal human IgG antipig antibodies.

  1996cites this paper
• Transgenic human decay accelerating factor makes normal pigs function as a concordant species.

  1996cites this paper